Large-Scale Computational Screening Identifies First in Class Multitarget Inhibitor of EGFR Kinase and BRD4

  title={Large-Scale Computational Screening Identifies First in Class Multitarget Inhibitor of EGFR Kinase and BRD4},
  author={Bryce K. Allen and Saurabh Jayesh Kumar Mehta and Stewart W. J. Ember and Ernst K Schonbrunn and Nagi G Ayad and Stephan C. Sch{\"u}rer},
  journal={Scientific Reports},
Inhibition of cancer-promoting kinases is an established therapeutic strategy for the treatment of many cancers, although resistance to kinase inhibitors is common. One way to overcome resistance is to target orthogonal cancer-promoting pathways. Bromo and Extra-Terminal (BET) domain proteins, which belong to the family of epigenetic readers, have recently emerged as promising therapeutic targets in multiple cancers. The development of multitarget drugs that inhibit kinase and BET proteins… 

Dual Kinase-Bromodomain Inhibitors in Anticancer Drug Discovery: A Structural and Pharmacological Perspective.

This manuscript will review the recent discoveries that led to the identification and optimization of dual kinase/bromodomain inhibitors, and analyze and compare the structural features required for dual inhibition and comment on the potential of this approach in anticancer drug discovery.

Computational Approaches in Multitarget Drug Discovery.

This chapter discusses concepts and research of bioactive multitargets related to toxicology, and proposes a virtual drug discovery that not only identifies efficient inhibitors but also helps to minimize side effects and toxicity, thus increasing the likelihood of successful therapies.

Structure-based pharmacophore mapping and virtual screening of natural products to identify polypharmacological inhibitor against c-MET/EGFR/VEGFR-2.

The filtered compound SN00020821, identified as Cedeodarin, demonstrated good interactions with all the three targets, c-MET/EGFR/VEGFR-2, with interaction energies and provides a novel molecular scaffold that could be investigated further as a polypharmacological anticancer therapeutic candidate that targets the three RTKs.

Machine-Learning-Assisted Approach for Discovering Novel Inhibitors Targeting Bromodomain-Containing Protein 4.

A novel, structure-based VS approach that uses machine-learning algorithms trained on the priori structure and activity knowledge to predict the likelihood that a compound is aBRD4i based on its binding pattern with BRD4 is demonstrated.

In silico study directed towards identification of novel high-affinity inhibitors targeting an oncogenic protein: BRD4-BD1

In silico screening of a small-molecule chemical library against the acetyl–lysine binding site of the first bromodomain (BD1) in BRD4 protein, identified potential inhibitors form direct and water-mediated hydrogen bonds with higher occupancy which may contribute to ligand specificity towards BRD 4-BD1.

Dual‐target inhibitors of bromodomain and extra‐terminal proteins in cancer: A review from medicinal chemistry perspectives

The protein structures and biological functions of BRD4 are summarized and the current design and discovery strategies for dual BET inhibitors are discussed, providing insight into potential discovery of additional dual‐target BET inhibitors.

Kinome-wide activity classification of small molecules by deep learning

This work evaluated multiple machine learning methods to predict small molecule inhibition of 342 kinases using over 650K aggregated bioactivity annotations for over 300K small molecules curated from ChEMBL and the Kinase Knowledge Base, demonstrating that multi-task deep neural networks outperform classical single-task methods.

Bromodomains: a new target class for drug development

The current state of BET inhibitor biology is reviewed, the next wave of bromodomain inhibitors with clinical potential in oncology and non-oncology indications are discussed, and the lessons learned from BET inhibitor programmes should affect efforts to develop drugs that target non-BET bRomodomains and other epigenetic readers.



Dual kinase-bromodomain inhibitors for rationally designed polypharmacology

It is reported that several clinical kinase inhibitors also inhibit bromodomains with therapeutically relevant potencies and are best classified as dual kinase/bromidomain inhibitors, a novel strategy for rational single agent polypharmacological targeting.

Receptor-Based Virtual Screening of EGFR Kinase Inhibitors from the NCI Diversity Database

Eight candidate compounds with high scoring functions that all bind to the ATP-competitive site of the EGFR-TK kinase are found and suggest that these molecules could be developed as novel lead compounds in anti-cancer drug design.

Discovery of Novel Small-Molecule Inhibitors of BRD4 Using Structure-Based Virtual Screening

This work provides a validated virtual screening approach that is applicable to other BRDs and describes novel KAc mimetics that can be further explored to design more potent inhibitors.

Targeting cancer with small-molecular-weight kinase inhibitors.

An insight is provided into protein and lipid kinase drug discovery with respect to achievements, binding modes of inhibitors, and novel avenues for the generation of second-generation kinase inhibitors to treat cancers.

Network Pharmacology Strategies Toward Multi-Target Anticancer Therapies: From Computational Models to Experimental Design Principles

A specific focus is on system-level network approaches to polypharmacology designs in anticancer drug discovery, where representative examples of how network-centric modeling may offer systematic strategies toward better understanding and even predicting the phenotypic responses to multi-target therapies are given.

Fragment-based drug discovery of 2-thiazolidinones as inhibitors of the histone reader BRD4 bromodomain.

After several rounds of structure guided modifications, the druggability of 2-thiazolidinone was assessed by modulating in vitro pharmacokinetic studies and cellular activity assay and the results showed that two potent compounds of2-th Diazolidinones have good metabolic stability.

Clinical Targeting of Mutated and Wild-Type Protein Tyrosine Kinases in Cancer

Evidence supporting the common mechanisms of protein tyrosine kinase activation in cancer is summarized and a personal perspective on the kinases BCR-ABL and BTK, as well as nonmutated kinase targets in prostate cancer, are provided.

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.

This review aims to highlight both the mechanisms of resistance that have already been identified in patients and potential novel mechanisms identified in preclinical models which have yet to be validated in the patient settings.